White House Imposes 50% Tariffs on Full Transaction Value in Section 232 Overhaul
April 6 proclamation shifts metals tariffs from content-based to full customs value, raising effective rates on derivatives while pharmaceutical and Iran actions weaponize supply chains.
The Trump administration invoked Section 232 national security authority on April 2, 2026, to restructure steel, aluminum, and copper tariffs effective April 6, shifting assessment from metal content to full customs value and imposing rates up to 50% on primary metals—a fundamental escalation in trade policy that raises input costs across automotive, aerospace, and defense sectors while concurrent pharmaceutical and Iran sanctions tighten supply chain leverage.
The proclamation introduces a tiered rate structure: 50% on articles made entirely or almost entirely of steel, aluminum, or copper (Annex I-A covering 554 products worth $96 billion); 25% on derivative articles substantially made of these metals (Annex I-B covering 326 products worth $227 billion); and 15% transitional rates on metal-intensive industrial and electrical grid equipment through December 31, 2027, according to White House fact sheets and Global Trade Alert analysis. Products made abroad entirely with U.S.-origin metals face a 10% rate, while items with 15% or less metal content by value escape Section 232 Tariffs entirely.
Full-Value Assessment Multiplies Effective Rates
The shift from metal-content-based to full customs value fundamentally alters tariff burdens. Under the prior regime imposed in June 2025, a 50% tariff applied only to the metal content portion of a product’s value. For products with 20% metal content, this yielded a 10% effective tariff. The new regime applies 25% to the full customs value of derivative products, raising the effective rate by 150% on the same item, per Global Trade Alert modelling.
The proclamation defines assessment methodology to “ensure tariffs reflect the full value of imported steel, aluminum, and copper products—not an artificially low foreign price,” according to the White House. This language signals customs enforcement focused on transaction value verification, raising compliance burdens for importers who must document metal sourcing and content across complex Supply Chains.
The UK receives preferential treatment—25% on Annex I-A products versus the standard 50%, and 15% on Annex I-B versus 25%—pending ongoing trade discussions, according to GHY International compliance guidance.
Cascading Supply Chain Impact
The derivative expansion hits automotive, aerospace, construction, and defense sectors hardest. Products with previously modest tariff exposure—machinery components, electrical equipment, fabricated metal articles—now face 25% rates on full value. The ongoing Israel-Hezbollah conflict in Lebanon and Yemen-Red Sea tensions have effectively shut the Strait of Hormuz since March 4, 2026, pushing Brent crude past $120 per barrel and disrupting an estimated 6.7 to 10+ million barrels per day of supply, compounding input cost pressures from the tariff restructuring.
The U.S. remains 100% import-reliant for 12 Critical Minerals and over 50% reliant for 29 additional materials essential to defense production, according to Commerce Department data cited in January 2026 White House proclamations. The Section 232 metals overhaul occurs alongside a January 14, 2026 directive for 180-day negotiations on processed critical minerals, with authority reserved to impose tariffs, quotas, or minimum import prices if talks fail by July 13, 2026.
Canada imposed 25% retaliatory tariffs on C$15.6 billion ($11 billion) of U.S. steel and aluminum as of September 2025, according to Congressional Research Service analysis, and had suspended further escalation pending negotiations. The April 6 restructuring—which raises effective rates on many products despite removing 144 items worth $183 billion from tariff scope—resets that calculus.
Pharmaceutical and Iran Leverage Plays
The April 2 proclamation package extends beyond metals. A concurrent action imposes 100% tariffs on patented pharmaceutical products and ingredients, effective July 31, 2026 for large companies and September 29, 2026 for smaller firms, with a tiered exception structure: 20% for companies with approved onshoring plans, 15% for EU/Japan/Korea/Switzerland/Liechtenstein producers, and 0% for those committing to most-favoured-nation pricing plus onshoring through January 20, 2029. The administration claims the pharmaceutical action spurred approximately $400 billion in new investment commitments, per the White House.
Secondary tariffs on countries acquiring goods or services from Iran, announced via executive order on February 6, 2026, add a third layer of supply chain coercion. The framework directs Commerce, State, and the U.S. Trade Representative to identify Iran-trading partners and impose tariffs—early reporting suggested 25% rates—on their exports to the U.S. Treasury Secretary cited 35% official inflation and 60% rial depreciation over 12 months as evidence of sanctions effectiveness, according to White House fact sheets.
Enforcement and Compliance Uncertainty
The proclamation terminates the prior derivative inclusion process, giving Commerce and USTR rolling authority to expand coverage without periodic presidential action. This creates ongoing uncertainty for manufacturers unsure whether their products will face reclassification. Documentation requirements intensify: importers must prove metal origin, content percentage, and transaction value authenticity to qualify for preferential rates or de minimis treatment.
Free trade zone treatment remains unclear in published guidance. Products entering FTZs before April 6 but not yet admitted to U.S. commerce face potential retroactive assessment under the new full-value methodology, according to ArentFox Schiff legal analysis.
What to Watch
Canadian and EU responses in the next 30 days will signal whether retaliatory escalation resumes. The July 13, 2026 deadline for critical minerals negotiations carries tariff authority if talks fail—watch for Commerce/USTR reporting in late June. Pharmaceutical tariff implementation guidance, due before July 31, will clarify onshoring criteria and country-specific exception eligibility. Iran secondary tariff country lists and rate schedules remain pending; any inclusion of major trading partners (India, Turkey, UAE) would trigger significant supply chain rerouting. Energy market stability hinges on Middle East conflict trajectory; sustained crude prices above $120 per barrel amplify inflationary pressure from tariff-driven input cost increases. Congressional attempts to invoke disapproval authority under the Congressional Review Act face tight timelines but merit attention given escalating Trade Policy unilateralism.